Figure 3

The two pre-erythrocytic vaccine models evaluated: 80% efficacy with nine-month halflife and 60% efficacy with three-year halflife.
The two pre-erythrocytic vaccine models evaluated: 80% efficacy with nine-month halflife and 60% efficacy with three-year halflife.